Cover Image
市場調查報告書

眼部發炎:開發中產品分析

Ocular Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 192745
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
眼部發炎:開發中產品分析 Ocular Inflammation - Pipeline Review, H1 2014
出版日期: 2014年04月30日 內容資訊: 英文 98 Pages
簡介

眼部發炎是指眼睛的中間層、葡萄膜的發炎。包含感染及發炎等各種原因造成眼睛發炎。症狀有充血、疼痛、畏光、流眼淚、眼壓上升等,對視覺有各種不同的影響。治療法有類固醇劑及瞳孔擴張藥。

本報告網羅全球眼部發炎治療藥的開發中產品相關資料,提供目前開發平台狀況和最新趨勢,後期階段及中止計劃的資訊,再加上主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

眼部發炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

眼部發炎:企業開發中的治療藥

眼部發炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

眼部發炎:企業開發中的產品

眼部發炎治療藥的開發企業

  • UMeWorld Limited
  • Sun Pharmaceutical Industries Limited
  • Bayer AG
  • InSite Vision Incorporated
  • Reata Pharmaceuticals, Inc.
  • Xigen SA
  • Enceladus Pharmaceuticals BV
  • SIFI S.p.A
  • Celsus Therapeutics Plc
  • Auven Therapeutics Management L.L.L.P
  • Cancer Therapeutics CRC Pty Ltd
  • Kala Pharmaceuticals, Inc.
  • Icon Bioscience, Inc.
  • Ocular Therapeutix, Inc.
  • Panmira Pharmaceuticals, LLC.
  • Clearside BioMedical, Inc.
  • Neuroptis Biotech

眼部發炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • bromfenac sodium
  • dexamethasone acetate
  • 地塞米松
  • mapracorat
  • dexamethasone acetateSR
  • XG-102
  • RX-10045
  • loteprednol etabonate
  • RTA-408
  • Triamcinolone acetonide
  • ketorolac tromethamine
  • AM-679
  • SF-110
  • SF-111
  • OPX-1
  • ARX-8203
  • NOP-5
  • Sun-0597
  • LIMK1 AND LIMK2抑制劑
  • SF-101
  • 微脂體皮質類固醇
  • puredonizoron

眼部發炎:最近的開發平台趨勢

眼部發炎:暫停中的計劃

眼部發炎:中止計劃

眼部發炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4829IDB

Global Markets Direct's, 'Ocular Inflammation - Pipeline Review, H1 2014', provides an overview of the Ocular Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ocular Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ocular Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ocular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ocular Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ocular Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ocular Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ocular Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Ocular Inflammation - Overview
    • Pipeline Products for Ocular Inflammation - Comparative Analysis
  • Ocular Inflammation - Therapeutics under Development by Companies
  • Ocular Inflammation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ocular Inflammation - Products under Development by Companies
  • Ocular Inflammation - Companies Involved in Therapeutics Development
    • UMeWorld Limited
    • Sun Pharmaceutical Industries Limited
    • Bayer AG
    • InSite Vision Incorporated
    • Reata Pharmaceuticals, Inc.
    • Xigen SA
    • Enceladus Pharmaceuticals BV
    • SIFI S.p.A
    • Celsus Therapeutics Plc
    • Auven Therapeutics Management L.L.L.P
    • Cancer Therapeutics CRC Pty Ltd
    • Kala Pharmaceuticals, Inc.
    • Icon Bioscience, Inc.
    • Ocular Therapeutix, Inc.
    • Panmira Pharmaceuticals, LLC.
    • Clearside BioMedical, Inc.
    • Neuroptis Biotech
  • Ocular Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bromfenac sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mapracorat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XG-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RX-10045 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTA-408 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triamcinolone acetonide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketorolac tromethamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-679 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SF-110 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SF-111 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPX-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARX-8203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NOP-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Sun-0597 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LIMK1 AND LIMK2 Inhibitors - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SF-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Liposomal corticosteroid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prednisolone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ocular Inflammation - Recent Pipeline Updates
  • Ocular Inflammation - Dormant Projects
  • Ocular Inflammation - Discontinued Products
  • Ocular Inflammation - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2014: Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone
      • Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition
      • Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery
      • Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone
      • Sep 24, 2013: Eleven Biotherapeutics to Present at the Targeting Ocular Disorders Conference
      • Jun 03, 2013: Ocular Therapeutix Completes Enrollment In Phase II Study For Sustained Release Dexamethasone
      • May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations
      • May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
      • May 08, 2013: Eleven Biotherapeutics Presents Clinical Data On EBI-005 At ARVO 2013 Annual Meeting
      • Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Inflammation, H1 2014
  • Number of Products under Development for Ocular Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Ocular Inflammation - Pipeline by UMeWorld Limited, H1 2014
  • Ocular Inflammation - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014
  • Ocular Inflammation - Pipeline by Bayer AG, H1 2014
  • Ocular Inflammation - Pipeline by InSite Vision Incorporated, H1 2014
  • Ocular Inflammation - Pipeline by Reata Pharmaceuticals, Inc., H1 2014
  • Ocular Inflammation - Pipeline by Xigen SA, H1 2014
  • Ocular Inflammation - Pipeline by Enceladus Pharmaceuticals BV, H1 2014
  • Ocular Inflammation - Pipeline by SIFI S.p.A, H1 2014
  • Ocular Inflammation - Pipeline by Celsus Therapeutics Plc, H1 2014
  • Ocular Inflammation - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2014
  • Ocular Inflammation - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014
  • Ocular Inflammation - Pipeline by Kala Pharmaceuticals, Inc., H1 2014
  • Ocular Inflammation - Pipeline by Icon Bioscience, Inc., H1 2014
  • Ocular Inflammation - Pipeline by Ocular Therapeutix, Inc., H1 2014
  • Ocular Inflammation - Pipeline by Panmira Pharmaceuticals, LLC., H1 2014
  • Ocular Inflammation - Pipeline by Clearside BioMedical, Inc., H1 2014
  • Ocular Inflammation - Pipeline by Neuroptis Biotech, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Ocular Inflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Ocular Inflammation - Dormant Projects, H1 2014
  • Ocular Inflammation - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Ocular Inflammation, H1 2014
  • Number of Products under Development for Ocular Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top